

Exjade - (125, 250, 500 mg Tablet For Suspension)

| | | | |
|------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | DEFERASIROX | Innovator | Novartis |
| Dosage | 125, 250, 500 mg Tablet For Suspension | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | Used to treat iron overload caused by blood transfusions in adults and children at least 2 years old | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.